07/29/2025
10:20 AM | Arrowhead Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SCHEDULE 13G/A | |
07/10/2025
3:30 PM | Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2025
9:26 AM | Arrowhead Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
| Form SCHEDULE 13G | |
04/23/2025
7:14 PM | Arrowhead Pharmaceuticals (Subject)
BlackRock, Inc. (Filed by)
| Form SCHEDULE 13G/A | |
04/11/2025
5:20 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/10/2025
3:35 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/09/2025
3:44 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/17/2025
4:45 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/13/2025
3:46 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/07/2025
3:15 PM | Arrowhead Pharmaceuticals (Filer)
| Form 424B7 | |
03/05/2025
5:32 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for ARWR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. |
03/04/2025
4:48 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/14/2025
8:31 AM | Arrowhead Pharmaceuticals (Subject)
Avoro Capital Advisors LLC (Filed by)
| Form SCHEDULE 13G/A | |
02/10/2025
5:23 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/07/2025
4:57 PM | Arrowhead Pharmaceuticals (Issuer)
INGRAM DOUGLAS S (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
02/07/2025
4:57 PM | Arrowhead Pharmaceuticals (Issuer)
INGRAM DOUGLAS S (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2025
5:41 AM | Arrowhead Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
| Form SCHEDULE 13G | |
01/27/2025
6:22 PM | Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/23/2025
3:43 PM | Arrowhead Pharmaceuticals (Subject)
OLUKOTUN ADEOYE Y (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/07/2025
8:27 PM | Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
8:28 PM | Arrowhead Pharmaceuticals (Issuer)
O'Brien Patrick (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
8:28 PM | Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/07/2025
3:49 PM | Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/07/2025
4:01 PM | Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/07/2025
3:31 PM | Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/06/2025
5:07 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/06/2025
4:48 PM | Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/06/2025
4:33 PM | Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/06/2025
4:40 PM | Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/06/2025
4:26 PM | Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/06/2025
4:19 PM | Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/06/2025
4:05 PM | Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/02/2025
3:16 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/30/2024
4:12 PM | Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/27/2024
3:23 PM | Arrowhead Pharmaceuticals (Subject)
OLUKOTUN ADEOYE Y (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/23/2024
3:39 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/23/2024
3:16 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/20/2024
5:04 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/20/2024
5:04 PM | Arrowhead Pharmaceuticals (Issuer)
Lu Hongbo (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/20/2024
5:04 PM | Arrowhead Pharmaceuticals (Issuer)
PERRY MICHAEL S (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/20/2024
5:04 PM | Arrowhead Pharmaceuticals (Issuer)
Ferrari Mauro (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
GENIUS Act: Cancel Your Money? (Ad) A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control.
Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live. Get the free info kit with 3 strategies to sidestep digital dollar control. |
12/20/2024
5:05 PM | Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/20/2024
5:05 PM | Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/20/2024
5:05 PM | Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/18/2024
5:15 PM | Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/18/2024
5:18 PM | Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/18/2024
5:19 PM | Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/18/2024
3:41 PM | Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/17/2024
4:06 PM | Arrowhead Pharmaceuticals (Subject)
GIVEN DOUGLAS B (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/17/2024
3:53 PM | Arrowhead Pharmaceuticals (Subject)
Waddill William D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/16/2024
3:44 PM | Arrowhead Pharmaceuticals (Subject)
Waddill William D. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/16/2024
3:15 PM | Arrowhead Pharmaceuticals (Subject)
GIVEN DOUGLAS B (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/15/2024
7:34 PM | Arrowhead Pharmaceuticals (Issuer)
Lu Hongbo (Reporting)
| Form 5
Annual statement of changes in beneficial ownership of securities | |
11/14/2024
8:38 AM | Arrowhead Pharmaceuticals (Subject)
Avoro Capital Advisors LLC (Filed by)
| Form SC 13G | |
10/16/2024
8:15 AM | Arrowhead Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
| Form SC 13G/A | |
